Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Silymarin for prevention of cisplatin-induced nephrotoxicity in upper gastrointestinal cancers
IRCT201207013043N6Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Aug 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of silymarin in esophageal cancer, gastric cancer (GC) and Cisplatin-Induced Nephropathy, sponsored by Tehran University of Medical Sciences. Started Aug 2012; status: completed.
02
Drugs
silymarin
03
Conditions
esophageal cancergastric cancer (GC)Cisplatin-Induced Nephropathy
Beyond the preview
Go deeper on IRCT201207013043N6.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT201207013043N6.